ClinicalTrials.gg

TargetBeta

FAS

Fas cell surface death receptor · also CD95, APO-1, FAS1, APT1 · CD molecules

1 program in company-led studies act on FAS, from 1 company: 0 in phase 3. Each with where its target was read from.

Programs

Furthest phase first. A target read by rule is marked rule (1 of them); the others are the company’s own words or a reading by Claude, each quoted on the program’s page.

ProgramCompanyFurthest phaseStudiesAlso acts onRead from
Autologous Priming Antigen-inducible Anti-PSMA CAR T-cells AB-3028ruleArsenal Biosciencesphase 210 runningFOLH1, TGFB1, TGFBR2NCIt

Also acted on by the same programs

Conditions their studies are in

What this can’t show

  • Only programs whose target has been read: most early programs are named only by a code and their companies do not say what they act on.
  • A target read by rule can be wrong; each program’s page quotes the words it was read from.
  • “Acts on” does not say how: an agonist and an antagonist of the same receptor are listed together (avexitide blocks the GLP-1 receptor that semaglutide activates).
  • Programs in company-led studies on ClinicalTrials.gov with a study in the last two years; academic studies and other registries are not counted here.